| 产品编号 | CFN91741 | |
| CAS编号 | 145-42-6 | |
| 分子式 = 分子量 | C26H44NNaO7S = 537.7 | |
| 产品纯度 | >=98% | |
| 物理属性 | Powder | |
| 化合物类型 | Steroids | |
| 植物来源 | ||
| ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用 | ||
| 产品名称 | 产品编号 | CAS编号 | 包装 | QQ客服 |
| 牛磺胆酸钠 | CFN91741 | 145-42-6 | 10mg | QQ客服:1413575084 |
| 牛磺胆酸钠 | CFN91741 | 145-42-6 | 20mg | QQ客服:1413575084 |
| 牛磺胆酸钠 | CFN91741 | 145-42-6 | 50mg | QQ客服:1413575084 |
| 牛磺胆酸钠 | CFN91741 | 145-42-6 | 100mg | QQ客服:1413575084 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)| Description: | Sodium taurocholate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Sodium taurocholate has immunoregulation effect. IC50 & Target:Microbial Metabolite; Human Endogenous Metabolite |
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8598 mL | 9.2989 mL | 18.5977 mL | 37.1955 mL | 46.4943 mL |
| 5 mM | 0.372 mL | 1.8598 mL | 3.7195 mL | 7.4391 mL | 9.2989 mL |
| 10 mM | 0.186 mL | 0.9299 mL | 1.8598 mL | 3.7195 mL | 4.6494 mL |
| 50 mM | 0.0372 mL | 0.186 mL | 0.372 mL | 0.7439 mL | 0.9299 mL |
| 100 mM | 0.0186 mL | 0.093 mL | 0.186 mL | 0.372 mL | 0.4649 mL |
| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 环氧长春碱,长春素; Vinleurosine | CFN90466 | 23360-92-1 | C46H56N4O9 = 808.95 | 5mg | QQ客服:1413575084 |
| 罗汉果苷IIe; Mogroside IIe | CFN92191 | 88901-38-6 | C42H72O14 = 801.0 | 10mg | QQ客服:3257982914 |
| 丹酚酸C; Salvianolic acid C | CFN98553 | 115841-09-3 | C26H20O10 = 492.44 | 20mg | QQ客服:1413575084 |
| Caboxine A; Caboxine A | CFN98901 | 53851-13-1 | C22H26N2O5 = 398.5 | 5mg | QQ客服:2159513211 |